Swiss National Bank Purchases 28,520 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Swiss National Bank grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 387,720 shares of the biopharmaceutical company’s stock after purchasing an additional 28,520 shares during the period. Swiss National Bank’s holdings in Alnylam Pharmaceuticals were worth $128,285,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ALNY. Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $241,000. Daiwa Securities Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the period. Finally, NewEdge Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 703 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 1.9%

Shares of ALNY opened at $272.67 on Tuesday. The stock has a 50 day moving average price of $293.92 and a 200 day moving average price of $319.69. Alnylam Pharmaceuticals, Inc. has a one year low of $266.27 and a one year high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The stock has a market capitalization of $36.40 billion, a price-to-earnings ratio of 74.50 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue was up 96.4% on a year-over-year basis. During the same period last year, the company posted ($0.44) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.26 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday, July 10th. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 7th. Finally, Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $455.31.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.